Top Markets
#1 ADO Protocol ADO Protocol +337.09%
#2 GoPlus Security GoPlus Security +52.33%
#3 Starpower Starpower +36.68%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.50%
#5 GAIB AID GAIB AID +24.67%
#6 Nockchain Nockchain +21.62%
#7 Tutorial Tutorial +21.22%
#8 OpenEden OpenEden +21.19%
#9 The Black Bull The Black Bull +20.93%
#10 Fake World Assets Fake World Assets +13.44%
Coin of the day
ADO Protocol ADO Protocol
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classement en actions #33301
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Prix de l'action
$0.4264
Dernière synchronisation: 2022-09-14
Capitalisation boursière
$7.93M
Changement (1 jour)
-16.44%
Changement (1 an)
0.00%
Pays
US
Échange Caladrius Biosciences, Inc. (CLBS)

Catégorie

Healthcare
Ratio P/B pour Caladrius Biosciences, Inc. (CLBS)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Caladrius Biosciences, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Caladrius Biosciences, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE